GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing SL Pharmaceutical Co Ltd (SZSE:002038) » Definitions » EBITDA Margin %

Beijing SL Pharmaceutical Co (SZSE:002038) EBITDA Margin % : 9.28% (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Beijing SL Pharmaceutical Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Beijing SL Pharmaceutical Co's EBITDA for the three months ended in Mar. 2025 was ¥15.7 Mil. Beijing SL Pharmaceutical Co's Revenue for the three months ended in Mar. 2025 was ¥168.9 Mil. Therefore, Beijing SL Pharmaceutical Co's EBITDA margin for the quarter that ended in Mar. 2025 was 9.28%.


Beijing SL Pharmaceutical Co EBITDA Margin % Historical Data

The historical data trend for Beijing SL Pharmaceutical Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing SL Pharmaceutical Co EBITDA Margin % Chart

Beijing SL Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.17 45.92 35.55 59.93 29.79

Beijing SL Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.91 14.39 -35.69 -28.77 9.28

Competitive Comparison of Beijing SL Pharmaceutical Co's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing SL Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing SL Pharmaceutical Co's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing SL Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Beijing SL Pharmaceutical Co's EBITDA Margin % falls into.


;
;

Beijing SL Pharmaceutical Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Beijing SL Pharmaceutical Co's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=196.726/660.42
=29.79 %

Beijing SL Pharmaceutical Co's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=15.671/168.896
=9.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing SL Pharmaceutical Co  (SZSE:002038) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Beijing SL Pharmaceutical Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Beijing SL Pharmaceutical Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing SL Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.69 Fu shi Road, No.1 Building, Bitongyuan, Haidian district, Beijing, CHN, 100049
Beijing SL Pharmaceutical Co Ltd is a Chinese biotechnology-pharmaceutical company. It is principally focused on developing and marketing gene engineering drugs. The product portfolio of the company includes drugs for Oncology, Hepatopathy and Senile disease. Its products include Filgrastim, Asparaginase, Dasartinib, Enoxaparin, Naftopidil, Ademetionine, Lenalidomide, and others.
Executives
Liang Shu Jie Secretary, Director
Xu Ming Bo Directors, executives
Yang Zhong Fan Supervisors
Chen Yu Lin Director
Qi Yan Ming Supervisors
Xi Wen Ying Executives
Wu Yan Zhuo Executives
Wang Wen Xin Director
Li Ya Jun Executives
Zhao Xia Securities Affairs Representative
Zhang Chun Lei Supervisors
Wang Yong Bo Directors, executives
Lu An Jing Supervisors
Wei Su Yan Director

Beijing SL Pharmaceutical Co Headlines

No Headlines